REDWOOD CITY, Calif. & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery ...
New QIAseq panels launched for use on next-generation sequencers to boost analysis of over 700 genes for comprehensive genomic profiling in research and clinical applications Advancing key ...
QIAGEN N.V. QGEN recently launched the digital PCR (polymerase chain reaction) Custom Assay Design Tool for copy number variation (CNV) analysis for use on the QIAcuity digital PCR (dPCR) platform.
Precision medicines and personalized treatments are revolutionizing cancer therapy. Small molecules, biological agents, antibody-drug conjugates and cell-based therapies directed against specific ...
Genomics England select QIAGEN’s Clinical Knowledge Base to power first-of-its-kind whole-genome sequencing study for newborns National study will screen newborns for more than 200 treatable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback